重要内容提示： | 回购方案首次披露日 | 2024/10/31 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 月 日~2025 年 10 | 10 | 29 | 月 28 | 日 | | 预计回购金额 | 2,200 万元~4,000 万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 889,185 | 股 | | | | | 累计已回购股数占总股本比例 | 0.2169% | | | | | | 累计已回购金额 | 元 11,946.559.53 | | | | | | 实际回购价格区间 | 12.17 元/股~15.13 元/股 | | | | | 一、回购股份的基本情况 江苏集萃药康生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召开第二届董事会第八次会议，审议通过了《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司 ...

Financial Performance - Total revenue for 2024 reached RMB 686.80 million, an increase of 10.38% compared to the previous year[3] - Net profit attributable to shareholders decreased by 27.14% to RMB 115.79 million[5] - Basic earnings per share decreased by 28.21% to RMB 0.28[3] Assets and Equity - Total assets at the end of the reporting period were RMB 2,576.24 million, a slight decrease of 0.05% from the beginning of the period[5] - The equity attributable to shareholders increased by 0.76% to RMB 2,140.77 million[5] Research and Development - The company maintained a high level of R&D investment, focusing on strategic projects such as "real-world animal models" and "antibody humanization"[6] Sales and Market Expansion - The company expanded its overseas sales team to over 40 members, covering key regions including North America, Asia-Pacific, and Europe[7] - Increased sales expenses due to the recruitment of additional sales personnel impacted profit margins[7] - The company emphasizes the importance of market expansion and infrastructure investment for future growth and profitability[7] Infrastructure and Operational Costs - New facilities in Beijing, Shanghai, and Guangdong have been completed and are now operational, contributing to increased depreciation expenses[7]

证券代码：688046 证券简称：药康生物 公告编号：2025-002 江苏集萃药康生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、回购股份的基本情况 江苏集萃药康生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召开第二届董事会第八次会议，审议通过了《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司使用自有资金和股票回购专项贷款资金以集中竞价 方式回购公司股份，回购股份将用于员工持股计划或股权激励，回购股份的资金 总额不低于人民币 2,200 万元（含），不超过人民币 4,000 万元（含），回购股份的 价格不超过人民币 18 元/股（含），回购股份的期限自董事会审议通过本次回购股 份方案之日起 12 个月内。具体内容详见公司分别于 2024 年 10 月 31 日、2024 年 11 月 8 日在上海证券交易所网站（www.sse.com.cm）上披露的《江苏集萃药康生 物科技股份有限公司关于以集中竞价交易方式回购公 ...

证券代码：688046 证券简称：药康生物 公告编号：2024-061 江苏集萃药康生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上述回购股份符合法律法规的规定及公司回购股份方案。 重要内容提示： | 回购方案首次披露日 | 2024/10/31 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 月 日~2025 年 10 | 10 | 29 | 月 28 | 日 | | 预计回购金额 | 2,200 万元~4,000 万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 369,185 | 股 | | | | | 累计已回购股数占总股本比例 | 0.0900% | | | | | | 累计已回购金额 | 元 5,20 ...

证券代码：688046 证券简称：药康生物 公告编号：2024-060 江苏集萃药康生物科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 12 月 03 日(星期二) 至 12 月 09 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@gempharmatech.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 江苏集萃药康生物科技股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日发布公司 2024 年三季度报告，为便于广大投资者更全面深入地了解公司 2024 年三季度经营成果、财务状况，公司计划于 2024 年 12 月 10 日下午 16:00- 17:00 举行 2024 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明 ...

Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [19][20]. Core Insights - The company reported a revenue of 510 million yuan for the first three quarters of 2024, representing a year-on-year growth of 12.13%. However, the net profit attributable to the parent company was 98 million yuan, down 16.57% year-on-year [1]. - The company is currently under profit pressure due to its expansion phase and increased costs associated with overseas market development. The sales expense ratio for Q3 2024 was 16.46%, up 4.85 percentage points year-on-year [2]. - The company is focusing on high-value mouse strains, having added over 200 new strains in the first half of 2024, and has initiated the Spotted Mouse 2.0 project to enhance data collection and application scenarios [2]. - The utilization rate of new facilities is steadily improving, with a total capacity of approximately 280,000 cages across seven domestic production facilities. The first overseas facility in San Diego has also been operational since Q1 2024 [2]. - The projected net profits for 2024-2026 are 149 million, 185 million, and 232 million yuan respectively, with corresponding EPS of 0.36, 0.45, and 0.56 yuan [2][3]. Financial Summary - Total revenue for 2023 is projected at 622 million yuan, with a year-on-year growth rate of 20.5%. The net profit for 2023 is estimated at 159 million yuan, reflecting a decline of 3.5% year-on-year [3]. - The company’s financial metrics indicate a PE ratio of 38 for 2023, decreasing to 26 by 2026, and a PB ratio of 2.9 in 2023, expected to drop to 2.5 by 2026 [3]. - The company’s total assets are projected to grow from 2,578 million yuan in 2023 to 3,270 million yuan by 2026, with a debt-to-equity ratio of 8.1% in 2023, increasing to 14.6% by 2026 [7].

江苏集萃药康生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召开第二届董事会第八次会议，审议通过了《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司使用自有资金和股票回购专项贷款资金以集中竞价 方式回购公司股份，回购股份将用于员工持股计划或股权激励，回购股份的资金 总额不低于人民币 2,200 万元（含），不超过人民币 4,000 万元（含），回购股份的 价格不超过人民币 18 元/股（含），回购股份的期限自董事会审议通过本次回购股 份方案之日起 12 个月内。具体内容详见公司分别于 2024 年 10 月 31 日、2024 年 11 月 8 日在上海证券交易所网站（www.sse.com.cm）上披露的《江苏集萃药康生 物科技股份有限公司关于以集中竞价交易方式回购公司股份方案的公告》及《江 苏集萃药康生物科技股份有限公司关于以集中竞价交易方式回购公司股份的回购 证券代码：688046 证券简称：药康生物 公告编号：2024-059 江苏集萃药康生物科技股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 ...

证券代码：688046 证券简称：药康生物 公告编号：2024-058 江苏集萃药康生物科技股份有限公司 关于以集中交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 江苏集萃药康生物科技股份有限公司（以下简称"公司"）拟通过集中竞价交 易方式回购部分公司已发行的人民币普通股（A 股）股票，回购方案具体如下： ● 回购股份金额：不低于人民币 2,200 万元（含），不超过人民币 4,000 万元 （含）； ● 回购股份资金来源：公司自有资金和股票回购专项贷款资金（包括兴业银 行股份有限公司南京建邺支行提供的股票回购专项贷款）； ● 回购股份用途：员工持股计划或股权激励； ● 回购股份价格：不超过人民币 18 元/股（含），该价格不高于公司董事会通 过回购方案决议前 30 个交易日公司股票交易均价的 150%； ● 回购股份方式：集中竞价交易方式； ● 回购股份期限：自公司董事会审议通过本次回购股份方案之日起12个月内； ● 相关股东是否存在减持计划：公司董事、监事、高级管理人员、控 ...

Investment Rating - The report maintains a "Buy" rating for the company [1][4]. Core Insights - The company reported a revenue of 510 million yuan for the first three quarters of 2024, representing a year-on-year increase of 12.1%. However, the net profit attributable to shareholders decreased by 16.6% to 98.21 million yuan, primarily due to increased costs associated with expansion and reduced government subsidies [2]. - The company is actively advancing multiple R&D projects, including the "Wild Mouse Project" and "Drug Screening Mouse Project," with a significant focus on expanding its overseas market, which generated revenue of 62.14 million yuan, a year-on-year increase of 44.9% [3]. - The projected net profit growth rates for 2024-2026 are -4.51%, 23.68%, and 15.47%, respectively, with corresponding EPS of 0.37, 0.46, and 0.53 yuan per share [4]. Summary by Sections Financial Performance - For Q3 2024, the company achieved a revenue of 170 million yuan, a 6.7% increase year-on-year, but the net profit dropped by 45.5% to 21.87 million yuan [2]. - The company’s revenue for 2024 is projected to be 693.34 million yuan, with a year-on-year growth of 11.44% [5]. R&D and Market Expansion - The company has launched 25 wild mouse strains and has over 100 strains in the R&D pipeline, with expectations to complete the initial screening of 80-100 strains by 2024 [3]. - The overseas market is becoming increasingly significant, contributing 18.26% to total revenue [3]. Profitability Forecast - The expected EPS for 2024 is 0.37 yuan, with a PE ratio of 37.23 [4]. - The company’s net profit is forecasted to decline in 2024 but is expected to recover in the following years, with growth rates of 23.68% and 15.47% in 2025 and 2026, respectively [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has shown steady revenue growth, but profit is under pressure due to increased expenses and ongoing expansion efforts [2] - In Q3 2024, the company achieved revenue of 1.69 billion yuan, a year-on-year increase of 12.13%, while the net profit attributable to the parent company was 0.22 billion yuan, a decrease of 45.51% year-on-year [2] - The company is actively expanding its overseas market presence, with production capacity utilization steadily improving [2] Financial Performance Summary - For the first three quarters of 2024, the company reported total revenue of 5.10 billion yuan, up 12.13% year-on-year, and a net profit of 0.98 billion yuan, down 16.57% year-on-year [2] - The company expects revenues for 2024, 2025, and 2026 to be 7.44 billion yuan, 8.80 billion yuan, and 10.28 billion yuan, respectively, with year-on-year growth rates of 19.7%, 18.2%, and 16.8% [2][4] - The net profit forecast for the same years is 1.56 billion yuan, 1.98 billion yuan, and 2.36 billion yuan, with year-on-year changes of -1.5%, 26.6%, and 19.2% [2][4] Capacity and Market Expansion - The company operates seven large production facilities in China, with a total capacity of approximately 280,000 cages [2] - The first overseas facility in San Diego, USA, has been operational since Q1 2024, enhancing the company's service capabilities for overseas clients [2] Key Financial Metrics - The company's revenue for 2023 is projected at 622 million yuan, with a year-on-year growth of 20.5% [4] - The gross profit margin is expected to decrease from 67.6% in 2023 to 62.9% in 2024 [4][7] - The company's P/E ratio is projected to decline from 51.67 in 2023 to 34.98 in 2024 [4][7]